S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Federal student loan payments are starting again. Here's what you need to know
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Federal student loan payments are starting again. Here's what you need to know
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Federal student loan payments are starting again. Here's what you need to know
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Federal student loan payments are starting again. Here's what you need to know
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
NASDAQ:MDWD

MediWound (MDWD) Stock Forecast, Price & News

$10.64
-0.23 (-2.12%)
(As of 09/29/2023 ET)
Compare
Today's Range
$10.44
$10.90
50-Day Range
$7.28
$10.87
52-Week Range
$7.10
$14.58
Volume
17,584 shs
Average Volume
37,558 shs
Market Capitalization
$97.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.00

MediWound MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
172.6% Upside
$29.00 Price Target
Short Interest
Healthy
0.78% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.71mentions of MediWound in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.52) to ($1.86) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.79 out of 5 stars

Medical Sector

809th out of 972 stocks

Medicinals & Botanicals Industry

8th out of 12 stocks


MDWD stock logo

About MediWound (NASDAQ:MDWD) Stock

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

MDWD Price History

MDWD Stock News Headlines

StockNews.com Upgrades MediWound (NASDAQ:MDWD) to "Hold"
Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
MediWound (NASDAQ:MDWD) PT Raised to $26.00 at HC Wainwright
Maxim Group Sticks to Their Buy Rating for Mediwound (MDWD)
Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
MediWound Announces Full Commercial Launch Of NexoBrid - Quick Facts
Maxim Group Sticks to Its Buy Rating for Mediwound (MDWD)
What 4 Analyst Ratings Have To Say About MediWound
MediWound Q2 2023 Earnings Preview
See More Headlines
Receive MDWD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediWound and its competitors with MarketBeat's FREE daily newsletter.

MDWD Company Calendar

Last Earnings
8/15/2023
Today
10/01/2023
Next Earnings (Estimated)
11/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medicinals & botanicals
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MDWD
Employees
83
Year Founded
2001

Price Target and Rating

Average Stock Price Forecast
$29.00
High Stock Price Forecast
$36.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+172.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-19,600,000.00
Pretax Margin
-55.19%

Debt

Sales & Book Value

Annual Sales
$26.50 million
Book Value
$1.51 per share

Miscellaneous

Free Float
8,359,000
Market Cap
$97.99 million
Optionable
Not Optionable
Beta
1.09

Social Links

The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Ofer Gonen B.Sc. (Age 50)
    Chief Exec. Officer
    Comp: $485k
  • Dr. Lior Rosenberg M.D. (Age 77)
    Co-Founder
    Comp: $727k
  • Dr. Ety Klinger MBA (Age 61)
    Ph.D., Chief R&D Officer
    Comp: $393k
  • Ms. Hani Luxenburg
    Chief Financial Officer
  • Mr. Tzvi Palash B.Sc. (Age 66)
    M.Sc., Chief Operating Officer
  • Mr. Yaron Meyer Adv. (Age 44)
    Exec. VP, Gen. Counsel & Corp. Sec.
  • Mr. Barry J. Wolfenson (Age 56)
    Exec. VP of Strategy & Corp. Devel.
  • Dr. Robert J. Snyder CWS (Age 73)
    D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc., Chief Medical Officer













MDWD Stock - Frequently Asked Questions

Should I buy or sell MediWound stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediWound in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MDWD shares.
View MDWD analyst ratings
or view top-rated stocks.

What is MediWound's stock price forecast for 2023?

4 Wall Street analysts have issued 12 month price targets for MediWound's stock. Their MDWD share price forecasts range from $25.00 to $36.00. On average, they anticipate the company's share price to reach $29.00 in the next twelve months. This suggests a possible upside of 172.6% from the stock's current price.
View analysts price targets for MDWD
or view top-rated stocks among Wall Street analysts.

How have MDWD shares performed in 2023?

MediWound's stock was trading at $13.49 at the beginning of 2023. Since then, MDWD shares have decreased by 21.1% and is now trading at $10.64.
View the best growth stocks for 2023 here
.

Are investors shorting MediWound?

MediWound saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 50,800 shares, an increase of 23.6% from the August 31st total of 41,100 shares. Based on an average daily volume of 17,900 shares, the short-interest ratio is presently 2.8 days. Currently, 0.8% of the company's shares are sold short.
View MediWound's Short Interest
.

When is MediWound's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 21st 2023.
View our MDWD earnings forecast
.

How were MediWound's earnings last quarter?

MediWound Ltd. (NASDAQ:MDWD) posted its quarterly earnings results on Tuesday, August, 15th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.41) by $0.51. The biopharmaceutical company had revenue of $4.77 million for the quarter, compared to the consensus estimate of $4.19 million. MediWound had a negative net margin of 55.53% and a negative trailing twelve-month return on equity of 71.45%.

When did MediWound's stock split?

MediWound's stock reverse split before market open on Tuesday, December 20th 2022. The 1-7 reverse split was announced on Tuesday, December 20th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

What other stocks do shareholders of MediWound own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MediWound investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), Blackstone (BX), Dynavax Technologies (DVAX), Geron (GERN), Idera Pharmaceuticals (IDRA), Mastercard (MA), SCYNEXIS (SCYX), Vascular Biogenics (VBLT) and Wells Fargo & Company (WFC).

What is MediWound's stock symbol?

MediWound trades on the NASDAQ under the ticker symbol "MDWD."

How do I buy shares of MediWound?

Shares of MDWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MediWound's stock price today?

One share of MDWD stock can currently be purchased for approximately $10.64.

How much money does MediWound make?

MediWound (NASDAQ:MDWD) has a market capitalization of $97.99 million and generates $26.50 million in revenue each year. The biopharmaceutical company earns $-19,600,000.00 in net income (profit) each year or ($2.4297) on an earnings per share basis.

How can I contact MediWound?

MediWound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The official website for the company is www.mediwound.com. The biopharmaceutical company can be reached via phone at 972779714100, via email at afields@lhai.com, or via fax at 972-77-971-4111.

This page (NASDAQ:MDWD) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -